
Ted G Laderas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5366699/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The consensus molecular subtypes of colorectal cancer. Nature Medicine, 2015, 21, 1350-1356.	30.7	3,596
2	CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood, 2019, 133, 588-599.	1.4	80
3	Metastability of a Supercompressed Fluid Monolayer. Biophysical Journal, 2003, 85, 3048-3057.	0.5	73
4	Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14331-14341.	7.1	55
5	The melting of pulmonary surfactant monolayers. Journal of Applied Physiology, 2007, 102, 1739-1745.	2.5	29
6	High throughput sequencing in mice: a platform comparison identifies a preponderance of cryptic SNPs. BMC Genomics, 2009, 10, 379.	2.8	20
7	Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia. Journal of Immunological Methods, 2018, 453, 44-52.	1.4	19
8	TandTRAQ: an open-source tool for integrated protein identification and quantitation. Bioinformatics, 2007, 23, 3394-3396.	4.1	15
9	Persistence of Metastability after Expansion of a Supercompressed Fluid Monolayer. Langmuir, 2004, 20, 4945-4953.	3.5	12
10	Consensus Framework for Exploring Microarray Data Using Multiple Clustering Methods. OMICS A Journal of Integrative Biology, 2007, 11, 116-128.	2.0	9
11	A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. Frontiers in Genetics, 2015, 6, 341.	2.3	9
12	Computational Detection of Alternative Exon Usage. Frontiers in Neuroscience, 2011, 5, 69.	2.8	8
13	Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia. Blood, 2016, 128, 4056-4056.	1.4	5
14	Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia. Blood, 2016, 128, 2829-2829.	1.4	4
15	Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. PLoS ONE, 2019, 14, e0223639.	2.5	2
16	Cerebrospinal Fluid (CSF) Proteomics in Children with Acute Lymphoblastic Leukemia (ALL) Blood, 2006, 108, 1834-1834.	1.4	1
17	Between Pathways and Networks Lies Context: Implications for Precision Medicine. Science Progress, 2015, 98, 253-263.	1.9	0
18	Abstract 603: Consensus molecular subtyping through a community of experts advances unsupervised		0

gene expression-based disease classification and facilitates clinical translation. , 2015, , .

TED G LADERAS

#	Article	IF	CITATIONS
19	Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness. Blood, 2018, 132, 2750-2750.	1.4	Ο
20	A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia. Blood, 2020, 136, 11-12.	1.4	0
21	Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. , 2019, 14, e0223639.		0
22	Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. , 2019, 14, e0223639.		0
23	Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. , 2019, 14, e0223639.		0
24	Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. , 2019, 14, e0223639.		0